The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...

Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...

Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to ...

The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer ...

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that ...

Bringing in a recruitment partner early gives sponsors the chance to test their protocols with real patients and gather ...

A settlement could extend the exclusivity of the world’s best-selling HIV medicine to 2036. Elsewhere, an AstraZeneca drug ...

A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema ...

Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...

AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, issues at a Novo plant are ...

CEO Joaquin Duato said the spinout will help the healthcare giant focus on medtech areas with higher growth and margins, such ...